BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Clofazimine\; the past or the future for TB treatment
DTSTART:20130610T110000
DTEND:20130610T120000
DTSTAMP:20260916T013455Z
UID:d9d244b2444b958668541203f8b095742712842ac0e8438deaf6758e
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Jacques Grosset\nClofazimine (CFZ) is sometimes administ
 ered to patients with multidrug-resistant tuberculosis (MDRTB)\,\ndespite 
 never having been evaluated for this purpose. We assessed the contribution
  of CFZ to a\nsecond-line regimen in a mouse model of MDR-TB. The addition
  of CFZ resulted in culture-negative\nlungs after 5 months of treatment\, 
 while mice receiving the non-CFZ-containing regimen remained\npositive aft
 er 9 months. The proportion of relapses was 3/15\, 3/15\, 5/15\, 1/14 and 
 1/15 among mice\ntreated with clofazimine for 5\, 6\, 7\, 8 and 9 months\,
  respectively (p>0.1). On average\, the rate of\nrelapse-free cure among c
 lofazimine-treated mice was 82.4%. In conclusion\, the clofazimine\ncontri
 bution was spectacular in the present experimental conditions.
LOCATION:AI 1153 https://plan.epfl.ch/?room==AI%201153
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR